If CMS cannot persuade GRAIL of the importance of randomization and using cancer death as the outcome, then it should cancel the study. The magnitude of the problem was evident in a major National ...
Jay Bhattacharya dismissed the test-negative design as 'crap.' The biostatistics literature tells a different story.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results